Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
18 sept. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
03 sept. 2024 16h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
22 août 2024 06h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
01 août 2024 16h10 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a clinical-stage biotechnology company developing a diverse pipeline of novel,...
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
01 août 2024 16h05 HE
|
Zymeworks Inc.
Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Priority Review of...
Zymeworks Announces Participation in Upcoming Investor Conferences
30 juil. 2024 06h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
25 juil. 2024 16h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
22 juil. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
11 juil. 2024 06h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
17 juin 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...